Rapid health technology assessment of linaclotide in the treatment of constipated irritable bowel syndrome

LENG Yujing; FANG Hufeng; YANG Hao; SU Dan

doi:10.6039/j.issn.1001-0408.2023.18.16

您当前的位置：

首页 >

文章列表页 >

Rapid health technology assessment of linaclotide in the treatment of constipated irritable bowel syndrome

更新时间：2025-09-26

- Rapid health technology assessment of linaclotide in the treatment of constipated irritable bowel syndrome
- ZHONGGUO YAOFANG Vol. 34, Issue 18, Pages: 2263-2268(2023)
- 作者机构：
  
  南京医科大学附属常州市第二人民医院药学部，江苏常州　213000
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2023.18.16
  CLC： R975
- Received：18 April 2023，
  
  Revised：2023-08-23，
  
  Accepted：25 August 2023，
  
  Published：30 September 2023
- 稿件说明：
移动端阅览
冷玉静,方胡凤,杨浩,等.利那洛肽治疗便秘型肠易激综合征的快速卫生技术评估[J].中国药房,2023,34(18):2263-2268.

LENG Yujing,FANG Hufeng,YANG Hao,et al.Rapid health technology assessment of linaclotide in the treatment of constipated irritable bowel syndrome[J].ZHONGGUO YAOFANG,2023,34(18):2263-2268.
冷玉静,方胡凤,杨浩,等.利那洛肽治疗便秘型肠易激综合征的快速卫生技术评估[J].中国药房,2023,34(18):2263-2268. DOI： 10.6039/j.issn.1001-0408.2023.18.16.

LENG Yujing,FANG Hufeng,YANG Hao,et al.Rapid health technology assessment of linaclotide in the treatment of constipated irritable bowel syndrome[J].ZHONGGUO YAOFANG,2023,34(18):2263-2268. DOI： 10.6039/j.issn.1001-0408.2023.18.16.

摘要

目的

对利那洛肽治疗便秘型肠易激综合征（IBS-C）的有效性、安全性及经济性进行综合评价，为临床应用提供循证依据。

方法

采用快速卫生技术评估方法。计算机检索PubMed、Embase、the Cochrane Library、Web of Science、中国知网、万方数据、维普网、中国生物医学文献服务系统以及卫生技术评估相关网站，收集利那洛肽治疗IBS-C的系统评价/Meta分析、HTA报告及药物经济学研究。筛选文献、提取资料和评价质量后，采用描述性分析对研究结果进行分类总结。

结果

共纳入11篇文献，其中7篇为系统评价/Meta分析、4篇为药物经济学研究。有效性方面，与安慰剂比较，利那洛肽可使IBS-C患者更快达到美国FDA推荐的联合终点和欧洲药品管理局建议的终点，显著改善患者完全自发排便应答、腹痛和便秘症状，提高生活质量，缓解患者整体症状；与鲁比前列酮、普卡那肽和替纳帕诺进行的间接证据比较结果显示，利那洛肽在FDA推荐的联合终点、完全自发排便应答、腹痛缓解率以及整体症状缓解率等方面的疗效更优。安全性方面，利那洛肽的总体不良反应、腹泻和胀气发生率均高于安慰剂，但患者均可耐受。经济性方面，与传统治疗药物相比，利那洛肽具有经济学优势。

结论

利那洛肽治疗IBS-C的有效性、安全性、经济性均有一定优势，是治疗IBS-C的有效策略。

Abstract

OBJECTIVE

To comprehensively evaluate the effectiveness， safety and economics of linaclotide in the treatment of constipated irritable bowel syndrome （IBS-C）， and to provide the evidence-based basis for clinical application.

METHODS

Rapid health technology assessment method was adopted； PubMed， Embase， the Cochrane Library， Web of Science， CNKI， Wanfang data， VIP database， SinoMed， and related HTA websites were searched. Systematic review/meta-analysis， HTA reports and pharmacoeconomic research about linaclotide were collected. After literature screening， data extraction and quality evaluation， descriptive analysis was used to classify and summarize the research results.

RESULTS

A total of 11 literature were included， involving 7 systematic reviews/meta-analyses and 4 pharmacoeconomic research. In terms of effectiveness， compared with placebo， linaclotide could achieve FDA specified endpoint and European Medicines Agency-recommended endpoint faster， significantly improved patients’ complete spontaneous bowel movements （CSBM）， abdominal pain， constipation and quality of life， and relieved patients’ global symptoms； compared with the indirect evidence of lubiprostone， plecanatide and tenapanor， the efficacy of linaclotide at the FDA specified endpoint， CSBM， abdominal pain relief， and global relief response were the best. In terms of safety， the incidence of overall adverse drug reactions， diarrhea and flatulence caused by linaclotide were significantly higher than placebo，but patients can tolerate them. In terms of economics， compared with traditional therapeutic drugs， linaclotide showed an economic advantage.

CONCLUSIONS

Linaclotide has advantages in efficacy， safety and economics in the treatment of IBS-C. It is an effective strategy for the treatment of IBS-C.

关键词

Keywords

references

胡玥，吕宾 . 肠易激综合征的治疗进展 [J ] . 中国实用内科杂志， 2020 ， 40 （ 2 ）： 105 - 110 .

SPERBER A D ， BANGDIWALA S I ， DROSSMAN D A ， et al . Worldwide prevalence and burden of functional gastrointestinal disorders，results of Rome foundation global study [J ] . Gastroenterology ， 2021 ， 160 （ 1 ）： 99 - 114.e3 .

NIEWINNA K ， ZIELIŃSKA A ， FICHNA J . Recent advances in the pharmacological management of consti-pation predominant irritable bowel syndrome [J ] . Expert Opin Pharmacother ， 2020 ， 21 （ 1 ）： 73 - 84 .

CAMILLERI M . Management options for irritable bowel syndrome [J ] . Mayo Clin Proc ， 2018 ， 93 （ 12 ）： 1858 - 1872 .

LOVE B L ， JOHNSON A ， SMITH L S . Linaclotide：a novel agent for chronic constipation and irritable bowel syndrome [J ] . Am J Health Syst Pharm ， 2014 ， 71 （ 13 ）： 1081 - 1091 .

唐惠林，门鹏，翟所迪 . 药物快速卫生技术评估方法及应用 [J ] . 临床药物治疗杂志， 2016 ， 14 （ 2 ）： 1 - 4 .

BENKHALTI M ， ESPINOZA M ， COOKSON R ， et al . Development of a checklist to guide equity considerations in health technology assessment [J ] . Int J Technol Assess Health Care ， 2021 ， 37 ： e17 .

葛龙，潘蓓，潘佳雪，等 . 解读AMSTAR-2：基于随机和（或）非随机对照试验系统评价的质量评价工具 [J ] . 中国药物评价， 2017 ， 34 （ 5 ）： 334 - 338 .

HUSEREAU D ， DRUMMOND M ， PETROU S ， et al . Consolidated health economic evaluation reporting standards（CHEERS） statement [J ] . BMC Med ， 2013 ， 11 ： 80 .

刘雪莲，杨见权，潘昭杰 . 利那洛肽治疗便秘型肠易激综合征的Meta分析 [J ] . 中国新药与临床杂志， 2013 ， 32 （ 8 ）： 650 - 655 .

ATLURI D K ， CHANDAR A K ， BHARUCHA A E ， et al . Effect of linaclotide in irritable bowel syndrome with constipation（IBS-C）：a systematic review and meta-analysis [J ] . Neurogastroenterol Motil ， 2014 ， 26 （ 4 ）： 499 - 509 .

黄显斌，郭天康，杨屹立，等 . 利那洛肽对便秘型肠易激综合征有效并改善患者生活质量的Meta分析 [J ] . 世界华人消化杂志， 2015 ， 23 （ 1 ）： 156 - 162 .

BLACK C J ， BURR N E ， QUIGLEY E M M ， et al . Efficacy of secretagogues in patients with irritable bowel syndrome with constipation：systematic review and network meta-analysis [J ] . Gastroenterology ， 2018 ， 155 （ 6 ）： 1753 - 1763 .

玉燕萍，郑松柏，张闪，等 . 利那洛肽治疗便秘型肠易激综合征的疗效和安全性的meta分析 [J ] . 胃肠病学， 2020 ， 25 （ 9 ）： 534 - 539 .

NAKAJIMA A ， SHOJI A ， KOKUBO K ， et al . A syste-matic review and network meta-analysis on the efficacy of medications in the treatment of chronic idiopathic constipation in Japan [J ] . Gastroenterol Res Pract ， 2021 ， 2021 ： 5534687 .

NELSON A D ， BLACK C J ， HOUGHTON L A ， et al . Systematic review and network meta-analysis：efficacy of licensed drugs for abdominal bloating in irritable bowel syndrome with constipation [J ] . Aliment Pharmacol Ther ， 2021 ， 54 （ 2 ）： 98 - 108 .

FISHER M ， WALKER A ， FALQUÉS M ， et al . Cost-effectiveness of linaclotide compared to antidepressants in the treatment of irritable bowel syndrome with consti-pation in Scotland [J ] . Eur J Health Econ ， 2016 ， 17 （ 9 ）： 1091 - 1100 .

HUANG H ， TAYLOR D C ， CARSON R T ， et al . Economic evaluation of linaclotide for the treatment of adult patients with irritable bowel syndrome with consti-pation in the United States [J ] . J Med Econ ， 2015 ， 18 （ 4 ）： 283 - 294 .

SHAH E D ， SALWEN-DEREMER J K ， GIBSON P R ， et al . Pharmacologic，dietary，and psychological treatments for irritable bowel syndrome with constipation：cost utility analysis [J ] . MDM Policy Pract ， 2021 ， 6 （ 1 ）： 238146832 - 0978417 .

XIAO D M ， ZHANG Y ， CHEN W X ， et al . Correction to：cost-effectiveness of linaclotide compared to osmotic laxatives in the treatment of irritable bowel syndrome with constipation in China [J ] . Adv Ther ， 2022 ， 39 （ 9 ）： 4394 - 4396 .

程能能 . 新型、口服肠上皮细胞鸟苷酸环化酶C激动剂：利那洛肽 [J ] . 中国临床药学杂志， 2019 ， 28 （ 4 ）： 291 - 295 .

邹多武 . 利那洛肽：慢性便秘和便秘型肠易激综合征的新选择 [J ] . 中华消化杂志， 2019 ， 39 （ 4 ）： 286 - 288 .

Views

245

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Dupilumab for the treatment of severe asthma： a rapid health technology assessment

Tenecteplase in the treatment of acute ischemic stroke： a rapid health technology assessment

Rapid health technology assessment of dapagliflozin in the treatment of type 2 diabetes mellitus combined with cardiovascular disease

Rapid health technology assessment of lorlatinib in the treatment of non-small cell lung cancer

Rapid health technology assessment of baloxavir marboxil in the treatment of influenza

Related Author

DONG Shichao

SUN Wei

WANG Huayu

WANG Ying

LI Huiting

MEN Peng

ZHANG Zhetao

ZHANG Jin

Related Institution

Dept. of Pharmacy，the Second Hospital of Tianjin Medical University

Dept. of Respiratory， the Second Hospital of Tianjin Medical University

Dept. of Pharmacy， the First Affiliated Hospital of USTC （Anhui Provincial Hospital）

Anhui Provincial Key Laboratory of Precision Pharmaceutical Preparations and Clinical Pharmacy

Dept. of Pharmacy， Peking University Third Hospital

Address：8th Floor, Sihuan Building, No. 129 Daping Main Street, Yuzhong District, Chongqing, China Postal code：400042
Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号公网安备50010302001817
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰